Hot COVID-19
Home > News > Lonza to Demonstrate Capabilities in Non-Viral or Viral CAR-T Research and Manufacturing at CAR-TCR Summit
Industry Updates New Products Supplier News Upcoming Events business web

Lonza to Demonstrate Capabilities in Non-Viral or Viral CAR-T Research and Manufacturing at CAR-TCR Summit

Hits:1504   Date: 9/1/2016
Cologne (DE) / Walkersville, MD (USA), 31 August 2016 – Lonza will present its capabilities in supporting the development of viral and non-viral CAR-T cell therapies at the upcoming CAR-TCR Summit in Boston, MA) (USA) from 13-16 September. This presentation includes the introduction of the new 4D-Nucleofector™ LV Unit, the latest addition to the proven 4D-Nucleofector™ System, which expands highly efficient, non-viral primary T cell transfection to a closed, larger-scale format. Lonza’s Nucleofector™ Technology improves on traditional electroporation methods to deliver enhanced transfection efficiencies while using less substrate and with only a moderate impact on cell viability.
 
The 4D-NucleofectorTM LV Unit complements Lonza’s comprehensive CAR-T service offerings, which include custom development and manufacturing of viral therapy and large-scale GMP manufacture of CAR-T cells.
 
At the Lonza booth # 7, delegates can:
 
   ·   Discover the new 4D-Nucleofector™ LV Unit for large-scale transfection
   ·   Learn about Lonza’s custom CAR-T services
   ·   Get a first glance of Lonza’s innovative patient-scale manufacturing technologies
   ·   Find out about Lonza’s serum-free media capabilities for hematopoietic cells
 
Lonza experts will also present on “Innovative Solutions for Manufacturing of Next-Generation Cell Therapies,” in which they will explore key topics such as overcoming manufacturing bottlenecks for CAR-T therapies, ensuring product quality and enabling commercially viable manufacturing through innovative platform technologies.
   ·   2:40-3:10 pm, 14 September 2016 (in the Manufacturing Track)
 
“Lonza’s Nucleofector™ Technology is an improved electroporation technique that has transformed transfection and allowed scientists to achieve results never possible before. The technology can particularly benefit those working with hard-to-transfect cell types, like primary blood cells or stem cells,” explained Herbert Mueller-Hartmann, Head of Research and Technology at Lonza. “The 4D-Nucleofector™ System was designed with the scientist in mind, so transfection protocols established on the existing smaller-scale unit can be smoothly transferred to the new large-scale unit without the need for re-optimization. The fully closed system is also suited for use in a regulatory environment as it can be controlled by 21 CFR Part 11-compatible software. The addition of this larger-scale transfection format allows us to accompany scientists as they translate the results of their research applications into potential therapeutic applications.”
 
Lonza provides the CAR-T market with end-to-end solutions for successful commercialization. These solutions include tools that can be used to develop and test therapeutics, ranging from cell culture and discovery technologies to quality control tests and process optimization. As a world-leading contract manufacturing organization (CMO), Lonza’s manufacturing services can supply researchers with clinical-grade raw materials such as specialized media formulations and virus batches. Lonza’s cellular manufacturing platforms remove supply bottlenecks and enable the CAR-T industry to provide commercially viable therapies at a global scale.
 
More information on how Lonza helps support the development and manufacture of viral and non-viral CAR-T cell therapies is available www.lonza.com/Car-T.  
 
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
 
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
 
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
 
Lonza Contact Information
Lonza Cologne GmbH
Lonza Group Ltd
Lonza Group Ltd
Manager Marketing Communications
Head Corporate Communications
Head External Communications
Petra Haberkamm
Dominik Werner
Constance Ward
Tel +49 221 991990
Tel +41 61 316 8798
Tel +41 61 316 8840
Fax +49 221 99199498
Fax +41 61 316 9540
Fax +41 61 316 9840
 
advertisement